
	Where results make sense

Topic: Schering

	Schering S.p.A. – Codice Etico (Site not responding. Last check: 2007-10-14)
		Schering is dedicated to operate in a manner that is economically, socially and environmentally responsible.
		Schering is committed to provide equal employment opportunities to all individuals and does not tolerate illegal discrimination or harassment of any kind.
		Schering undertakes to deliver full, fair, accurate, timely and understandable disclosure in all reports and documents filed or submitted by it under German law, or with the United States Securities and Exchange Commission, and in its other public communication.
	www.schering.it /scripts/st/10_about/code/english/index.php (1528 words)

	Complaint: SEC v. Schering-Plough Corporation
		Finally, Schering disclosed in its Form 10-Q that it expected U.S. wholesalers to deplete their prescription Claritin inventories by year end, with the majority being worked down in the third-quarter, and that it expected this to have an approximately $250 million negative impact on Schering's pretax profits for the remainder of 2002.
		Several months earlier, Schering had publicly warned that it expected its third-quarter earnings to be "significantly lower than the comparable period in 2001," but the company had never publicly commented on Wall Street analysts' earnings estimates for the quarter nor provided any other quantitative guidance suggesting that estimates were too high.
		Schering subsequently reported actual EPS of $0.29 for the third quarter and $1.34 for the full 2002 fiscal year, while lowering its EPS guidance for the full 2003 fiscal year to a range of $0.75 to $0.85.
	www.sec.gov /litigation/complaints/comp18330.htm (2266 words)

	Schering UK: About Schering UK (Site not responding. Last check: 2007-10-14)
		Schering is committed to developing new and innovative therapies for severe and chronic diseases.
		Schering is convinced of the benefits of cooperation with patient organisations in fostering communication and partnership to achieve the best outcomes of medical care for patients.
		Schering was the first in the UK to offer a treatment for certain forms of MS when in 1995, a beta-interferon was approved for the relapsing-remitting form of the disease.
	www.schering.co.uk /content/global/about_updated_version.asp (1120 words)

	About Schering Oy
		About Schering Oy Schering Oy is a dynamic research-based pharmaceutical company and a leader in its areas of expertise.
		Schering developes medicines of high clinical value and tailored therapies to give people with life-threatening diseases new perspectives.
		Schering Oy is the largest international pharmaceutical company of foreign origin in Finland.
	www.schering.fi /scripts/EN/10_About/index.php (139 words)

	Schering-Plough Corporation and Richard J. Kogan: Admin. Proc. Rel. No. 34-48461 / September 9, 2003
		During the week of September 30, 2002, Kogan, Schering's then chairman and chief executive officer, along with Schering's senior vice president of investor relations, met privately in Boston, Massachusetts with analysts and portfolio managers of four institutional investors, three of which were among Schering's largest investors.
		Finally, Schering disclosed that it expected U.S. wholesalers to deplete their prescription Claritin inventories by year end, with the majority being worked down in the third-quarter, and that it expected this to have an approximately $250 million negative impact on Schering's pretax profits for the remainder of 2002.
		Although Schering and Kogan were free to convey the serious concerns they had over Schering's earnings prospects to industry professionals, Schering had a legal obligation to disseminate that information to the rest of the marketplace in accordance with Regulation FD.
	www.sec.gov /litigation/admin/34-48461.htm (3161 words)

	Working at Schering
		Schering Canada’s success stems from the men and women who are the foundation of its organization.
		Schering Canada values the potential and skill development of all its employees to promote mobility within the organization, including lateral or vertical transfers or transfer to other regions.
		Schering employees show and live by these core values in their work.
	www.schering.ca /english/careers/default.asp?s=1 (451 words)

	Schering Commemorative Mortar & Pestle Series
		The Schering Corporation was established in the United States in 1928 as a subsidiary of Schering AG.
		It is also important to note that Schering AG and Schering Corporation have been operating independently from each other since World War II and maintain their own separate identities.
		Mike had started with Schering in 1970 and although he has not been with the company since the inception of the mortar & pestle series, he has the most knowledge of anyone with the company at this time.
	www.frontiernet.net /~barthology/index.html (2295 words)

	WebWire® \| Bayer makes official takeover offer for Schering
		According to the offer document, Schering AG shareholders can submit a written letter of acceptance to the bank that administers their securities account by the end of the acceptance period at midnight CEST on May 31, 2006.
		Schering shareholders can therefore not rely on definitely being able to accept the Bayer offer during the additional acceptance period.
		Schering’s stock market listing in Switzerland and registration in the United States in accordance with the U.S. Securities Exchange Act of 1934 could be terminated as well, to the extent that this move would be compliant with statutory regulations.
	www.webwire.com /ViewPressRel.asp?aId=12642 (1203 words)

	Schering - Wikipedia, the free encyclopedia
		Schering AG (FWB:SCH, NYSE: SHR) is a research-centered pharmaceutical company founded in 1851.
		Schering's annual gross revenue was nearly € 5 billion (2003).
		Schering best-known product is probably the birth control pill.
	en.wikipedia.org /wiki/Schering (217 words)

	Schering lowers 2003 earnings guidance - Mar. 5, 2003
		Schering said the loss of Claritin will also hit its first-quarter profit, now expected to be about 10 cents a share.
		Schering blamed the shortfall on the company's transition away from Claritin, which last year lost patent protection and now sells over the counter at much lower prices.
		Schering has not been accused of violating fair disclosure rules, which mandate that companies release material information to all investors simultaneously.
	money.cnn.com /2003/03/05/news/companies/schering/index.htm (544 words)

	Schering Latina
		Schering es una compañía farmacéutica con investigación propia.
		Schering está representada a lo largo del mundo por más de 140 subsidiarias y compañías asociadas.
		Hoy día, Schering AG mantiene en casi todos los países de Latinoamérica una filial propia, cubriendo las necesidades de los restantes mercados a través de distribuidores locales.
	www.scheringlatina.com.mx /home/mundo.asp (204 words)

	Schering AG Makes Biotech Strides - Forbes.com (Site not responding. Last check: 2007-10-14)
		Schering (nyse: SHR - news - people) is a world leader in birth control and dyes used for diagnostic imaging, with annual sales of $4 billion.
		For Schering, which has been making strides into biotech and cancer treatment with a treatment for multiple sclerosis and Campath, a cancer drug licensed from Ilex Oncology (nasdaq: ILXO - news - people), it is a strategic step forward.
		Besides, Schering has cash to burn after getting rid of its share of the crop science division of Aventis (nyse: AVE - news - people) when the unit was sold to Bayer (nyse: BAY - news - people).
	www.forbes.com /technology/futuretech/2002/05/03/0503schering.html (760 words)

	Schering (Site not responding. Last check: 2007-10-14)
		Schering uses best efforts to include accurate and up-to-date-information on this site, but makes no warranties or representations (either expressed or implied) as to its accuracy, completeness, adequacy, comprehensiveness or up-to-dateness.
		Schering accepts no responsibility with regard to damages caused by the access to or use of such Third Party Contents or with regard to its availability from this site.
		Schering sites are designed to provide information and resources to those who use them.
	www.schering.lt /legal_statements.html (872 words)

	Schering Group - Homepage
		As part of its Responsible Care program, Schering aims to reduce its use of energy and the amount of CO2 emissions on a global scale.
		It is planned that Schering AG will be renamed Bayer Schering Pharma Aktiengesellschaft.
		A corresponding resolution was passed at the Extraordinary General Meeting of Schering AG on September 13, 2006.
	www.schering.de /scripts/en/index.php (185 words)

	Home - HE Clissmann - Schering AG - Ireland (Site not responding. Last check: 2007-10-14)
		HE Clissmann and Schering AG celebrate 50 years of working together, improving healthcare in Ireland.
		HE Clissmann is an Irish family firm which represents Schering AG in Ireland since 1950.
		Schering AG is an international research-based pharmaceutical company.
	www.clissmann.com /schering (203 words)

	Internationale actualiteit
		The Executive Board of Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced that it will support a voluntary public offer by Bayer AG to acquire all of the outstanding shares of Schering AG for a price of EUR 86 in cash which it will recommend to its shareholders after having assessed the offer documents.
		Schering and Bayer have agreed to combine both businesses in a manner which balances the interests of all stakeholders.
		Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
	www.schering.nl /scripts/nl/30_press/32_inter/PR_23_03_2006.php (638 words)

	Schering-Plough
		The Commission's administrative complaint alleges that Schering, the maker of K-Dur 20, a widely prescribed potassium chloride supplement, illegally paid Upsher-Smith and American Home Products millions of dollars to induce them to delay launching their generic versions of the drug beyond any delay they might have agreed to without such payments.
		Although under the agreement Schering received licenses to market five of Upsher-Smith's products, the complaint charges that these products were of little value to Schering and that the $60 million payment had little relation to the value of those products.
		In June 1998, the FTC's complaint alleges, Schering and ESI settled the patent infringement case with an agreement by which ESI, in exchange for payments from Schering, promised not to market any generic version of K-Dur 20 until January 2004.
	www.ftc.gov /opa/2001/04/schering.htm (1089 words)

	Chemical & Engineering News: Latest News - Schering Shares
		Germany's Merck, which had acquired a 21.8% stake in Schering and thus threatened Bayer's agreement to acquire Schering, agreed to offer its stake to Bayer.
		Merck began buying Schering shares on the stock market on June 9, in what it subsequently said was a move to secure its long-term strategic interest in Schering.
		Schering Escapes Merck's Grasp CandEN, April 3, 2006
	pubs.acs.org /cen/news/84/i25/8425notw5.html (318 words)

	Schering UK: specialising in female healthcare, therapeutics, diagnostics and dermatology (Site not responding. Last check: 2007-10-14)
		Schering Health Care is the UK subsidiary of Schering AG,
		The latest medical information on Schering's therapy areas, products, selected journal abstracts, information for patients and links to associated websites.
		Detailed patient information on Schering's health topics including educational leaflets, fact sheets and links to recommended sites.
	www.schering.co.uk (139 words)

	Schering AG News (via CobWeb/3.1 planetlab2.cs.unc.edu) (Site not responding. Last check: 2007-10-14)
		Indevus Pharmaceuticals Inc. has signed an agreement with Germany's Schering AG to be its U.S. supplier of an injectable treatment for low testosterone, or hypogonadism, officials say.
		Xanthus Pharmaceuticals, Inc. has licensed from Schering AG the exclusive right to develop and commercialize oral fludarabine in the U.S. Oral fludarabine is currently marketed by Schering AG in the EU under...
		Organon and Schering AG have announced that their research collaboration into a male hormonal contraceptive will conclude at the end of the phase II clinical trial.
	www.topix.net.cob-web.org:8888 /com/shr (767 words)

	Schering AG (Site not responding. Last check: 2007-10-14)
		Schering AG As a successful pharmaceutical company, we are investing in the future of medicine.
		We develop drugs of high medical value so as to continuously improve the quality of life.
		As a global player with over 140 subsidiaries we are in close contact with our customers around the world.
	www.schering.com /scheringag_popup.html (116 words)

	Internationale actualiteit
		Prior to joining Schering in 2005, Zündorf held positions within Sanofi-Aventis Corporation, where he headed the Marketing and Sales organization of Aventis Pharma Germany and was later accountable as General Manager for Commercial Operations.
		In Oncology, Schering AG maintains a prominent leadership position by offering a range of hematological and solid tumor treatments.
		Schering AG is strongly invested in bringing to market an innovative and broad oncology R&D portfolio of systemic and targeted therapies, potentially offering novel therapeutic options for people with cancer.
	www.schering.nl /scripts/nl/30_press/32_inter/PR_26_01_2006.php (324 words)

	Schering - Waar kan u ons vinden
		Schering is located a 15 minutes walk from the NS-station.
		After 300 meters you'll find Schering at your right hand side.
		Schering is situated at your right in about 300m.
	www.schering.nl /scripts/nl/00_meta/contact/wayto.php?back=index.php (234 words)

	Schering Forschungsgesellschaft (Ernst Schering Research Foundation) (Site not responding. Last check: 2007-10-14)
		The Ernst Schering Research Foundation was established in June 1991 with the objective of promoting outstanding scientific research in the fields of biology, medicine and chemistry.
		As a result of its initiatives and programs, the Ernst Schering Research Foundation serves as a bridge between academia and industry, thus advancing the fruitful dialog between basic science and applied research.
		The Ernst Schering Research Foundation ceased its activities as of the end of 2005.
	www.schering-fg.de /html/index-en.html (111 words)

	Schering AG ADR Stock Report (SHR) \| Quote & News
		Schering AG and Organon to Continue Research in Male Fertility Control Separately (PRN)
		Schering AG Licenses SEGRA Compound for Ophthalmic Use to Bausch & Lomb (PRN)
		Schering operates its pharmaceutical business in North America under the Berlex name.
	quote.morningstar.com /Switch.html?ticker=SHR (267 words)

	Commission Rules Schering-Plough, Upsher, and Ahp Illegally Delayed Entry of Lower-Cost Generic Drug
		According to the Commission’s opinion, Schering and its potential generic competitors, Upsher and AHP, had settled patent litigation with terms that included unconditional payments by Schering in return for agreements to defer introduction of the generic products.
		The Commission has challenged other settlements as anticompetitive, and obtained consent orders in the past; the Schering opinion, released today, however, marks the first time the Commission has addressed the legality of settlements with the benefit of a full administrative trial and record.
		The factual question, according to the opinion, was whether Schering had paid $60 million to Upsher for licenses or for delay.
	www.ftc.gov /opa/2003/12/schering.htm (1020 words)

	Former activities of the Ernst Schering Research Foundation (Site not responding. Last check: 2007-10-14)
		From 1991 to 2005 the Ernst Schering Research Foundation sponsored scientific workshops held with internationally acknowledged experts on selected topics of basic research in the fields of biology, medicine and chemistry.
		The lectures during the workshops are published by Springer-Verlag under the title of "Ernst Schering Research Foundation Proceedings" and are available from the bookstore or the Science Office.
		The Schering Foundation maintains the tradition of these workshops and has also initiated a new symposium program.
	www.schering-fg.de /html/former-en.html (189 words)

	C&EN: TODAY'S HEADLINES - Schering-Plough Awaits Indictment
		Schering-Plough says it has received a letter from the U.S. Attorney's Office for the District of Massachusetts advising the company that its subsidiary, Schering Corp., is the target of a federal grand jury investigation.
		The company says it "understands that, based on Department of Justice guidelines, receipt of a 'target' letter indicates the government intends to pursue an indictment and believes it has substantial evidence to support that indictment."
		Schering says it has implemented changes to its sales, marketing, and clinical trial practices and is continuing to review those practices to ensure compliance with relevant laws and regulations.
	pubs.acs.org /cen/topstory/8123/8123notw3.html (120 words)

	Schering-Plough - Wikipedia, the free encyclopedia
		Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG's U.S. assets be seized.
		In 1971, the Schering Corporation merged with Plough to form Schering Plough.
		Today Schering Plough manufactures several pharmaceutical drugs, the most well-known of which are the allergy drugs Claritin and Clarinex, and through a collaboration with Merck and Co., Zetia, an anti-cholesterol drug.
	en.wikipedia.org /wiki/Schering-Plough (571 words)

Try your search on: Qwika (all wikis)